Press "Enter" to skip to content

Basilea starts phase 1/2 study with derazantinib in urothelial cancer – GlobeNewswire

admin 0

Basilea starts phase 1/2 study with derazantinib in urothelial cancer  GlobeNewswire

Basel, Switzerland, August 13, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the phase 1/2 FIDES-02 study with the …

“bladder cancer” – Google News

(Visited 4 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *